Lung Cancer Vaccines are called biological response modifiers because they restore or stimulate the ability of the immune system to fight disease and infection, according to the National Cancer Institute. Lung cancer vaccines can help prevent cancer from developing that is preventive or prophylactic vaccines or helps in treating cancer once it has developed. Due to the favorable initiatives are taken by the World Health Organization and increasing awareness regarding lung cancer prevention and treatment there is increasing the opportunity for market growth, while some of the factors like side effects associated with the lung cancer vaccines and inadequate access to it is creating a hindrance for the market.
- Growing Government Support for Lung Cancer Vaccines Development
- Increased Awareness about the Disease Prevention and Treatment
- Rising Focus on Immunization Programs
- Technology Advancement in Lung Cancer Vaccines
- Technological Advancement with the Innovations of Different Possible Therapies for Cancer
- Side Effects Associated With Lung Cancer Vaccines Such As Redness and Pain At The Site of Injection, Fever, and Fatigue & Muscles Pains
The key Players profiled in the report are Ono Pharmaceutical (Japan), Boehringer Ingelheim (Germany), Eli Lily (United States), GlaxoSmithKline (United Kingdom), Cascadian Therapeutics, Inc (United States), Merck (United States), CureVac (Germany), PDC*line Pharma (France), Aduro BioTech Inc. (United States) and Amgen (United States). Additionally, other players that are part of this comprehensive study are Astellas Pharma Inc (Japan), Bristol-Myers Squibb (United States) and Dendreon (United States).